There is no single BPC-157 dosage that applies to every patient
Liraglutide, the first long acting GLP-1RA was approved 12 years ago with a black box warning for MTC based on rodent data
Kismet typically recommends weekly or monthly treatments based on lab results and symptoms
Evidence quality varies a lot depending on which BPC-157 claim you are looking at, and treating all of it as equally solid is a mistake
Those arent the only BCAA benefits either
In occlusion/occlusion-like syndromes affecting both periphery and brain (portal hypertension, caval hypertension, intracranial hypertension), BPC-157 simultaneously normalized blood pressure disturbances, healed gastrointestinal and liver lesions, minimized brain lesions and hemorrhage, prevented thrombosis, and preserved neurological function